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Abstract
Low-income and middle-income countries (LMICs) are undergoing an epidemiological transition, in which the burden of
noncommunicable diseases (NCDs) is rising and mortality will shift from infectious diseases to NCDs. Specifically, cardiovascular
disease, diabetes, renal diseases, chronic respiratory diseases, and cancer are becoming more prevalent. In some regions, particularly
sub-Saharan Africa, the dual HIV and NCD epidemics will pose challenges because their joint burden will have adverse effects
on the quality of life and will likely increase global inequities. Given the austere clinical infrastructure in many LMICs, innovative
models of care delivery are needed to provide comprehensive care in resource-limited settings. Improved data collection and
surveillance of NCDs among HIV-infected persons in LMICs are necessary to inform integrated NCD-HIV prevention, care, and
treatment models that are effective across a range of geographic settings. These efforts will preserve the considerable investments
that have been made to prevent the number of lives lost to HIV, promote healthy aging of persons living with HIV, and contribute
to meeting United Nations Sustainable Development Goals.
(JMIR Public Health Surveill 2018;4(4):e10989)  doi: 10.2196/10989
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The HIV and NCD Syndemic
In high-income countries, antiretroviral therapy (ART) has
improved the survival of persons living with HIV (PLHIV),
resulting in declines in morbidity and mortality and a shift in
the natural history of HIV disease [1-3]. With ART scale-up in
the low-income and middle-income countries (LMICs), similar
epidemiologic transitions are expected, resulting in an expanding
and aging HIV population [4,5]. Since 2004, the US President’s
Emergency Plan for AIDS Relief (PEPFAR), in collaboration
with local governments, has established HIV prevention, care,
and treatment programs in over 30 countries worldwide [6], and
the Global Fund to Fight HIV, Tuberculosis and Malaria has
funded programs in more than 100 countries, including some
PEPFAR-funded countries [7]. Globally, the provision of ART
accelerated dramatically over the past decade, supporting 19
million PLHIV on ART through June 2016. When the Joint
United Nations Programme on AIDS (UNAIDS) [8] 90-90-90
goals (90% of people with HIV diagnosed, 90% of them on
ART, and 90% of them virally suppressed by 2020) are realized,
AIDS-related opportunistic infections will become rare [9], and
noncommunicable diseases (NCDs) will become increasingly
prevalent among PLHIV [10-16].
The natural history of HIV for persons who are stable on ART
is that HIV becomes a chronic disease with an increased risk
of chronic comorbidities. These chronic conditions include, but
are not limited to, cardiovascular disease [17], depression
[18-20], cancers [21,22], and metabolic abnormalities, including
insulin resistance with consequent dyslipidemia, type 2 diabetes,
and lipodystrophy [23-25]. The increased prevalence of NCDs
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among HIV-infected adults reflects a combination of factors,
including aging, a greater prevalence of traditional risk factors,
infection with oncogenic viruses, direct consequences of HIV
(eg, inflammation), and exposure to specific antiretrovirals
[26-36]. A recent systematic review examined the prevalences
of the following 4 NCDs (and their risk factors) in LMICs that
are known to commonly occur among PLHIV: cardiovascular
disease, cervical cancer, mental health, and type 2 diabetes [37].
However, data were sparse for some diseases entities.
Increasing patient awareness of the effects of long-term HIV
infection and effective levels of antiretroviral treatment, that is,
viral suppression, particularly the shift to a predominance of
chronic diseases, is important because this improved awareness
may prompt patients to report symptoms and request screening
for related conditions. Therefore, patient education can improve
our ability to detect NCDs as they become more prevalent. An
effective public health response to HIV, now that the epidemic
is maturing, requires treatment and prevention of NCDs among
PLHIV in LMICs. It is imperative to understand the predominant
risk factors, the consequent symptoms and complications, and
the available appropriate treatments and preventative
interventions for each NCD.
If left unaddressed, NCDs may undermine the gains in healthy
life-years realized by global health investments in HIV
prevention and treatment [38]. The emerging NCD epidemic
presents a unique opportunity to leverage the tremendous
investments made in the existing HIV health platforms so that
these enhanced health systems can deliver improved HIV care,
which includes the prevention and treatment of chronic
comorbidities to achieve further reductions in preventable
deaths. Additionally, lessons learned from the public health
approach in response to the HIV epidemic could be applied to
the care and treatment of NCDs, given the chronic nature of
both conditions. To understand this emerging syndemic,
improved surveillance and clinical monitoring of NCDs among
PLHIV are necessary to estimate the burden of and risk factors
for NCDs among HIV-infected persons.
HIV surveillance has been shifting with the epidemic response
over the past 2 decades. Reliance on sentinel surveys and AIDS
case reporting was augmented with household surveys,
community-based surveys, and HIV case reporting. The current
trend is to move toward more routine data collection activities.
Patient monitoring systems that capture a variety of health
conditions, such as routine perinatal mother-to-child
transmission surveillance, are becoming more important as
increasing numbers of PLHIV are accessing care and treatment.
Some comorbidities are already recognized as important to
monitor, though these are primarily infectious, such as
tuberculosis, hepatitis B, and hepatitis C. As effective ART
continues to be scaled up across LMICs, chronic conditions will
become more important to monitor because more PLHIV will
achieve virologic suppression.
National HIV program responses would benefit from the
integration of screening for NCDs known to be associated with
or closely linked to HIV, for example, human
papillomavirus-related cancers, such as cervical cancer, and
cardiovascular disease [37]. As indicated by a recent systematic
review, current efforts are limited to clinical cohorts or studies
[37]. Routine screening is not presently being conducted in
many clinical settings in sub-Saharan Africa (SSA) that offer
HIV care; however, some efforts do exist [39]. General
screening could include blood pressure measurement, height
and weight assessment, lifestyle counseling including smoking
cessation and physical activity promotion, tests for liver and
kidney function, and cervical cancer screening. Given the
similarities between HIV and NCD care and management, a
coordinated approach to address both seems feasible and
warranted [40]. Additionally, the resultant health systems’
strengthening will facilitate improvements in health care
coverage worldwide.
Benefits of Noncommunicable
Diseases-HIV Integration
The PEPFAR HIV program has been criticized as a vertical
disease-specific health system with regards to funding, supply
chain, and clinician staffing [41-43]. Horizontal integration
avoids these issues by taking a multi-disease approach to care
[43,44]. Models such as chronic disease clinics have proven
effective in treating diabetes, hypertension, and HIV and allow
caregivers to take a patient-centered approach in responding to
the health needs of PLHIV [45]. By preventing late-stage NCD
presentation, horizontally-integrated care models minimize
NCD-related mortality and may thus maximize cost-
effectiveness if cost-prudent integration is employed [38].
Integrated models of care have also shown increased retention
of patients with comorbid disease, thereby conferring
improvements in adherence to treatment and continuity of care
[41,43]. Lastly, integration of HIV and NCD monitoring and
evaluation (M&E) systems allows for improved data collection
and analysis pertaining to NCDs, which could then be used to
support large-scale health policy change [46].
Barriers to Integration
The integration of NCD and HIV health care can lead to
improvements in the quality of care and treatment; however,
this enhancement of service provision can be costly. Initial
overhead costs needed for service integration include training
of clinical staff, procurement and distribution of laboratory
reagents and medications, and greater supply chain needs. These
costs can often be daunting for policy makers in resource-limited
settings [47]. In integrated care systems, deficits in human
resources for health, such as limited numbers of health care
workers, can become problematic owing to the need for
increased requirements for clinical services. Deficits here can
lead to bottlenecking because of high patient loads and increased
responsibilities for few clinicians [48,49]. Task-shifting can
alleviate this bottleneck, but the cost of additional staff and
training may be prohibitive.
Economically, integrating NCD care into LMIC HIV systems
is only viable with buy-in from the government, external donors,
and national constituents. As with PEPFAR for HIV care,
countries may require infrastructural capacity building before
they become capable of supporting these larger health care
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systems on their own [50]. Although not universally feasible,
an ideal solution would entail HIV programs providing the
necessary infrastructure for NCD programs with multi-sectoral
support and coordination, thus minimizing cost [51]. As
countries transition from low-income to middle-income, an
additional challenge is finding resources to support HIV
programs as donor resources diminish in the face of competing
health care demands. These demands include the need for
additional financial and human resources in constrained
situations. Finally, the integration of separate health systems
creates a need for improved management practices. Standards
to address selection biases, validity, and reliability of data
sources are needed to ensure that robust data are collected. This
will ensure that data from a variety of sources (eg, clinical
systems, research, and M&E) are standardized to some extent
and will limit missing and unreliable data. M&E systems must
be expanded to include NCD screening and treatment services,
and quality of care must be ensured through continued
monitoring, evaluation, and medical education [43,49,52].
As NCDs become more prevalent, resource allocation needs to
be informed by knowledge of the burden of disease and
evidence-based interventions. Cost-effective models of
comprehensive care of HIV, a chronic disease when viral
suppression is achieved and maintained, that integrates
management of NCDs associated with HIV are needed. The
first step is leveraging surveillance systems to enhance our
knowledge of the NCD burden among PLHIV by collecting
information on risk factors and related morbidity. Several
strategies to improve knowledge of disease burden exist,
allowing public health officials to design or enhance
interventions to reduce years of life lost. Among these are
case-based surveillance and population-level monitoring
systems; registries, which use medical records data for clinical
surveillance; cohort monitoring in LMICs; and population-based
surveys.
Case-Based Reporting and
Population-Level Patient Monitoring
Systems
HIV case reporting has been a part of second generation
surveillance, as proposed by the World Health Organization
(WHO) and UNAIDS, since 2000 [53]. Case-based reporting
systems remain unevenly developed across LMICs [54,55]. The
rapid expansion of ART and the promulgation of the 90-90-90
treatment targets have renewed the focus on case reporting,
linked to patient monitoring systems, by WHO and UNAIDS.
In settings where unique identifiers are available, HIV case
report systems can be crossed with registries where they exist
to link associated conditions; currently, cancer registries are the
most prevalent [56]. Every effort should be made to protect
patient privacy and ensure confidentiality as individual systems
grow to collect more data elements and are linked to other
systems. To strengthen overall patient care, the population-level
HIV patient monitoring system, which is designed to track ART
adherence and HIV viral suppression, can monitor conditions
associated with both HIV infection and long-term exposure to
ART. Population-level patient monitoring systems can capture
risk factors such as hypertension and hyperlipidemia as well as
outcomes such as cardiovascular disease and cancer [57].
Specific conditions that have a demonstrated link to HIV
infection or long-term use of ART should be collected and
reported, and appropriate responses should be developed for
the patient and the population.
Registries
Registries collect clinical information of all patients diagnosed
with a certain condition within a particular catchment area over
a period of time and are particularly useful for patient care,
especially in areas that lack population-level patient monitoring
systems. Patients’ information from participating clinics is
entered into the registry after diagnosis of a particular NCD or
identification of a person with previously diagnosed NCD(s)
of interest; this registry contains all patients under the same
participating health care provider or in the same facility who
have the same NCD. The clinic data collected at each visit is
entered into the registry or, ideally, automatically flows from
the patients’ medical records into the registry without additional
resources required for data entry[58]. These data can then be
aggregated at the regional or national level and can be used for
cohort monitoring; program evaluation; tracking indicators for
accountability to funders, policy makers, and stakeholders; and
for performance reporting. Furthermore, at the patient level,
registries can be used to track adherence, provide reminders for
follow-up and preventative services as well as track health
changes over time [59].
Registries range from a low-tech paper-based format to a
higher-tech electronic format. An electronic medical records
(EMRs) system is ideal because it allows for the data to be
collected in real-time from a linked EMRs system, and
individual or cohort outcomes can be more easily monitored.
However, an EMR is not necessary [60]. As the number of cases
grows, as expected for an NCD of interest, paper-based registries
cannot work efficiently or accurately. Collecting patient data
and manually creating a registry is time-consuming and takes
health care staff away from patient care [61]. However, it is still
a useful modality, and the lack of EMRs systems should not
preclude the development of registries, at least in part, for
improving patient care.
The creation of registries is important and prudent because the
current management of NCDs is, in many places, unstructured
and unmonitored. Through the creation of registries, health care
systems can gain the ability to collect data on NCDs [62].
Reliable patient data at all levels are necessary for surveillance,
forecasting drug and commodity procurement, human resource
needs, and logistics required to keep the program on track [63].
However, it is important to ensure that any new data collection
requirements render useful information and do not create an
additional burden for the health care staff. Registries can also
be structured to give feedback on performance, which serves
as a benchmark to determine the quality of care and quality
improvement at the level of individual providers, health care
teams, or clinics. Registries can also be used to support clinical
decision making; to allow providers to be proactive rather than
reactive, for example, by setting up patient reminders about
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needed services or follow-up visits; and to share data throughout
a practice, among practices, and potentially throughout an entire
health care system.
Ethical considerations may prevent the inclusion of name-based
HIV status in a registry, requiring unique identifiers. However,
even with unique identifiers, confidentiality may be lost if
systems are not created with checks to ensure privacy. Therefore,
precautions to protect the identity of individuals in both
name-based HIV case report databases as well as databases that
use unique identifiers must be taken, particularly in contexts
where stigma and discrimination against PLHIV are strong.
Cohort Monitoring
An important use of registries is cohort monitoring [64], which
is inspired by directly observed treatment, short-course for
tuberculosis and provides a useful way of assessing whether
interventions, as specified in the country guidelines for NCDs,
are being performed as well as to track performance and
progress of the intervention. This allows the country to review
the progressive scale-up of those alive and on treatment and see
where these patients are being treated (hospital, urban health
center, rural health center, or private clinic). Furthermore,
individual patient data can be deidentified and aggregated to
determine morbidity and mortality levels for NCDs generally,
generate incidence and prevalence rates of complications, and
assess performance at local and national levels [59]. Successful
application of the directly observed treatment, short-course
monitoring system to patients with diabetes in Malawi [58] and
those with hypertension in Jordan [61] has been reported.
Population-Based Surveys
The WHO-UNAIDS Technical Working Group on HIV
Surveillance has advocated the use of population-based surveys
to understand the risk factors for HIV and to determine HIV
incidence and prevalence. As the HIV epidemic matures in SSA,
these surveys should include questions about NCDs and related
risk factors. Basic screening for diseases such as hypertension
would be easy to employ as well [65]. Household surveys such
as the Demographic and Health Surveys (DHS) collect data on
screening for NCDs and HIV. Some DHS include testing for
NCDs and HIV [66,67]; however, it is uncommon for DHS to
routinely report on any associations. These data are publicly
available and can be examined for associations, but this should
become part of routine public health reporting. Additionally,
the WHO STEPwise approach to surveillance should consider
an HIV module for high-burden countries. This would allow
for both general population and HIV-specific estimates of NCD
burden, which would inform national policies and plans to
address the growing NCD burden.
The PEPFAR-funded Population-based HIV Impact Assessment
surveys are nationally representative, household-based HIV
surveys that are used to provide subnational estimates for HIV
prevalence and viral load suppression and national estimates
for HIV incidence to measure the status of the HIV epidemic
and impact of HIV prevention and treatment programs [68].
Data on demographic characteristics, risk behaviors, and testing
and treatment history are collected through household and
individual questionnaires. These surveys can also be leveraged
to collect data about NCDs by including questions about NCD
risk factors and diagnosed NCDs. Additionally, HIV testing is
routinely performed with laboratory capacity to test blood
samples, which provides an opportunity for screening for NCDs
as well.
Mathematical Modeling
Given the limited data currently available concerning the NCD
burden among PLHIV in LMICs, mathematical modeling could
provide useful information about prevalence. The granularity
of the prevalence rates may be limited based on available
country-specific data for the models. However, with concerted
efforts to collect meaningful data to inform these models,
relevant figures could be generated. Currently, the Global
Burden of Disease Study generates estimates for the prevalence
of various diseases and has a Web-based tool that generates
visualizations of these data [69]. As a next step, it may be
imperative to develop a tool to generate the estimates of
coburden of certain diseases such as HIV and tuberculosis or
HIV and cardiovascular disease. Data of coburden can help us
to identify syndemics and thus better focus our efforts and
resources to prevent and treat these diseases.
Conclusions
With the success of the global effort to scale up ART access,
LMICs, particularly those in SSA, in which mortality has been
dominated by HIV over the past decades, will start to experience
syndemics. Increasingly, mortality attributable to NCDs will
be greater than communicable diseases as it is in the rest of the
world. Improved data collection and surveillance of NCDs
among HIV-infected persons in LMICs are necessary to inform
integrated NCD-HIV prevention, care, and treatment models
that are effective across a range of geographic settings.
Implementation of integrated care will strengthen current health
systems and facilitate a platform for more comprehensive and
less fragmented health care delivery as well as M&E systems.
These efforts will preserve the considerable investments that
have been made to prevent lives lost to HIV, promote healthy
aging of PLHIV, and contribute to meeting United Nations
Sustainable Development Goals [70]. Additional incremental
investments in NCD management among PLHIV could broaden
health care coverage and support a research agenda, which
would benefit both PLHIV and the general population.
Furthermore, as countries start to achieve HIV epidemic control,
the integration of HIV and NCD management will provide a
transition plan for extending the comprehensive care provided
to PLHIV to the general population; this will facilitate the goal
of improved overall access to health care.
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